Case Report
CellMed 2022; 12(4): 18.1-18.2
Published online November 30, 2022
https://doi.org/10.5667/CellMed.2022.018
© Cellmed Orthocellular Medicine and Pharmaceutical Association
Ortho-Cellular Nutrition Therapy (OCNT) Prescription for Patients with Bronchiectasis and End-stage Liver Cancer
Correspondence to : Haninhee Onnuri Pharmacy
In Korea, liver cancer is the sixth most prevalent malignancy and the second leading cause of cancer-related mortality. The peak incidence of liver cancer deaths occurs between the ages of 40 and 59. (e.g. Yoon et al. 2021) The patient is a 69-year-old female with bronchiectasis as an underlying condition. She underwent left lower lobe resection for the disease, and in 2009 she was diagnosed with liver cancer and experienced a recurrence after a full recovery. In the case of such patients, the most effective OCNT prescription is recommended.
Keywords Ortho-Cellular Nutrition Therapy; OCNT; End-stage Liver Cancer; Liver Cancer
PDF
Standard view
Export citation
Share Article
Case Report
CellMed 2022; 12(4): 18.1-18.2
Published online November 30, 2022 https://doi.org/10.5667/CellMed.2022.018
Copyright © Cellmed Orthocellular Medicine and Pharmaceutical Association.
Ortho-Cellular Nutrition Therapy (OCNT) Prescription for Patients with Bronchiectasis and End-stage Liver Cancer
Han, Inhee
Haninhee Onnuri Pharmacy
Correspondence to:Haninhee Onnuri Pharmacy
Abstract
In Korea, liver cancer is the sixth most prevalent malignancy and the second leading cause of cancer-related mortality. The peak incidence of liver cancer deaths occurs between the ages of 40 and 59. (e.g. Yoon et al. 2021) The patient is a 69-year-old female with bronchiectasis as an underlying condition. She underwent left lower lobe resection for the disease, and in 2009 she was diagnosed with liver cancer and experienced a recurrence after a full recovery. In the case of such patients, the most effective OCNT prescription is recommended.
Keywords: Ortho-Cellular Nutrition Therapy, OCNT, End-stage Liver Cancer, Liver Cancer
